Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$4.13 -0.5%	$2.88	$1.03 ▼ $4.40	$827.40M	1.54	7.18 million shs	3.58 million shs
ORIC Oric Pharmaceuticals	$9.24 -4.0%	$10.23	$3.90 ▼ $14.67	$787.43M	1.69	1.24 million shs	1.05 million shs
SOPH SOPHiA GENETICS	$3.16 -1.4%	$3.23	$2.58 ▼ $4.92	$214.90M	1	81,476 shs	24,088 shs
UPB Upstream Bio	$16.00 +1.0%	$12.04	$5.14 ▼ $29.46	$862.56M	N/A	458,020 shs	214,758 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	-0.96%	+57.63%	+186.81%	+225.20%
ORIC Oric Pharmaceuticals	0.00%	-8.70%	-16.76%	+70.79%	+10.13%
SOPH SOPHiA GENETICS	0.00%	-0.16%	-9.60%	-0.79%	-2.62%
UPB Upstream Bio	0.00%	+2.96%	+39.37%	+68.42%	+1,599,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	2.7659 of 5 stars	4.7	1.0	0.0	1.1	1.7	0.6
ORIC Oric Pharmaceuticals	4.2289 of 5 stars	3.5	1.0	4.4	3.1	3.3	0.6
SOPH SOPHiA GENETICS	2.2285 of 5 stars	3.5	3.0	0.0	2.6	0.0	0.6
UPB Upstream Bio	1.7134 of 5 stars	3.5	0.0	0.0	1.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.40	Buy	$11.25	172.40% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	100.99% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	153.57% Upside
UPB Upstream Bio	3.00	Buy	$56.50	253.13% Upside

Current Analyst Ratings Breakdown

Latest SOPH, UPB, ORIC, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $15.00
7/29/2025	ATAI atai Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
7/28/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	2,669.05	N/A	N/A	$0.69 per share	5.99
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A
SOPH SOPHiA GENETICS	$69.69M	3.06	N/A	N/A	$1.48 per share	2.13
UPB Upstream Bio	$2.37M	363.95	N/A	N/A	$8.77 per share	1.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)
SOPH SOPHiA GENETICS	-$62.49M	-$0.44	N/A	N/A	N/A	-40.99%	-30.69%	-17.39%	N/A
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	-3,836.58%	-35.90%	-26.26%	N/A

Latest SOPH, UPB, ORIC, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	UPB Upstream Bio	-$0.61	-$0.74	-$0.13	-$0.74	$0.32 million	$0.94 million
8/5/2025	Q2 2025	SOPH SOPHiA GENETICS	-$0.25	$0.33	+$0.58	$0.33	$17.49 million	$18.32 million
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
ORIC Oric Pharmaceuticals	N/A	12.00	12.00
SOPH SOPHiA GENETICS	0.62	3.39	3.21
UPB Upstream Bio	N/A	38.27	38.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
ORIC Oric Pharmaceuticals	95.05%
SOPH SOPHiA GENETICS	31.59%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
ORIC Oric Pharmaceuticals	5.55%
SOPH SOPHiA GENETICS	4.88%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
ORIC Oric Pharmaceuticals	80	85.22 million	80.49 million	Optionable
SOPH SOPHiA GENETICS	520	67.58 million	64.28 million	Not Optionable
UPB Upstream Bio	38	53.91 million	46.60 million	N/A

SOPH, UPB, ORIC, and ATAI Headlines

Recent News About These Companies

William Blair Lowers Earnings Estimates for Upstream Bio

August 10 at 2:19 AM | americanbankingnews.com

Q3 EPS Estimates for Upstream Bio Cut by William Blair

August 9 at 7:49 AM | marketbeat.com

Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

August 8 at 2:44 PM | finance.yahoo.com

Upstream Bio (UPB) Q2 R&D Soars 169%

August 6, 2025 | fool.com

Upstream Bio, Inc. reports Q2 results

August 6, 2025 | seekingalpha.com

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

August 6, 2025 | globenewswire.com

Upstream Bio (UPB) Expected to Announce Earnings on Tuesday

August 3, 2025 | americanbankingnews.com

Upstream Bio (NASDAQ:UPB) Stock Price Up 8.1% - Still a Buy?

July 31, 2025 | marketbeat.com

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions

July 28, 2025 | tipranks.com

Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment

July 28, 2025 | tipranks.com

Upstream Bio Inc. (UPB) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Upstream Bio (NASDAQ:UPB) Trading Up 10% - Still a Buy?

July 25, 2025 | marketbeat.com

Upstream Bio begins phase 2 COPD trial for verekitug

July 10, 2025 | uk.investing.com

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...

July 8, 2025 | bakersfield.comB

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio

July 8, 2025 | quiverquant.comQ

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

July 8, 2025 | globenewswire.com

UPB Upstream Bio, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 15, 2025 | msn.com

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress

June 15, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Vertical Aerospace Stock Trades at Discount After VX4 Milestone
By Jeffrey Neal Johnson | July 22, 2025
View Vertical Aerospace Stock Trades at Discount After VX4 Milestone
PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
By Thomas Hughes | July 19, 2025
View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom

SOPH, UPB, ORIC, and ATAI Company Descriptions

atai Life Sciences NASDAQ:ATAI

$4.13 -0.02 (-0.48%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.12 -0.01 (-0.36%)

As of 05:52 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Oric Pharmaceuticals NASDAQ:ORIC

$9.24 -0.39 (-4.05%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$9.24 0.00 (0.00%)

As of 04:03 AM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

SOPHiA GENETICS NASDAQ:SOPH

$3.16 -0.05 (-1.41%)

Closing price 08/8/2025 03:58 PM Eastern

Extended Trading

$3.20 +0.05 (+1.43%)

As of 04:30 AM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Upstream Bio NASDAQ:UPB

$16.00 +0.16 (+1.01%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$15.69 -0.31 (-1.94%)

As of 08/8/2025 06:31 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time